Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial
Dinah S Reddihough, Catherine Marraffa, Anissa Mouti, Molly O'Sullivan, Katherine J Lee, Francesca Orsini, Philip Hazell, Joanna Granich, Andrew JO Whitehouse, John Wray, David Dossetor, Paramala Santosh, Natalie Silove, Michael Kohn
JAMA | AMER MEDICAL ASSOC | Published : 2019
Importance: Selective serotonin receptor inhibitors are prescribed to reduce the severity of core behaviors of autism spectrum disorders, but their efficacy remains uncertain. Objective: To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders. Design, Setting, and Participants: Multicenter, randomized, placebo-controlled clinical trial. Participants aged 7.5-18 years with autism spectrum disorders and a total score of 6 or higher on the Children's Yale-Brown Obsessive Compulsive Scale, modified for pervasive developmental disorder (CYBOCS-PDD) were recruited from 3 tertiary health centers across Australia...View full abstract
Awarded by NHMRC
The study was funded by the NHMRC (NHMRC project grant 607332) (Drs Reddihough, Marraffa, Hazell, Lee, Kohn, andWray) and the Royal Children's Hospital Foundation, Melbourne, Australia (Dr Reddihough). Infrastructure support was provided by the Victorian government's Operational Infrastructure Support Program. The Murdoch Children's Research Institute, Melbourne, was the sponsor for this study.